Clinical Trials Logo

Clinical Trial Summary

Recurrent miscarriage (RM) defined by >=3 consecutive losses affects 1% of fertile couples. Most women have recurrent early loss with a failure of development before 10 weeks' gestation. Standard investigations fail to reveal any apparent cause in >50% of couples. No study has demonstrated any benefit of any medication in women with Unexplained RM, in the presence or absence of an inherited thrombophilia. Moreover, the benefit of aspirin and/or heparin has not been proved in women with Antiphospholipid (APL) antibody without other clinical manifestations of Antiphospholipid Syndrome. Hydroxychloroquine (HQ) is a molecule whose properties (anti-thrombotic, vascular-protective, immunomodulatory, improved glucose tolerance, lipid-lowering, anti-infectious) could be useful against mechanisms of Unexplained RM. There is no data concerning the benefit of HQ in RM in the presence or absence of antiphospholipid antibodies or any inherited thrombophilia. Administration in (Systemic Lupus erythematosus (SLE) women and for Malaria prevention provides extensive safety data during pregnancy. Oral administration makes possible treatment since the preconception period. For all of that and its low cost, hydroxychloroquine should be evaluated in RM whatever the woman thrombophilic status.


Clinical Trial Description

Regarding the mechanisms of unexplained RM, on the basis of animal models and clinical studies, many hypotheses were raised: - Reduced ovarian reserve, - Progesterone defect: a double-blind trial did not show any benefit of progesterone therapy. - Thrombotic mechanisms and/or endothelial dysfunction: An association with some inherited thrombophilias was suggested. A prothrombotic state outside of pregnancy was measured in women with previous RM and without known thrombophilia. - Immunological disturbances (high titers of anti-thyroid or APL antibodies, maternal carriage of specific HLA alleles and immunological reactions against male-specific minor antigens, increased numbers of peripheral blood natural killer, overexpression of TOLL receptors, increase of TH1 and TH17 processes). Consequently, immunomodulatory treatments were proposed and assessed (no impact of intravenous immunoglobulins and no conclusive benefit of corticosteroids). - Miscellaneous: BMI> 30 and chronic endometritis. Besides, the experience gained from previous clinical trials in RM leads us to emphasize, that subcutaneous administration of heparin limits its assessment among fertile women. Indeed, the treatment could not be administrated before conception and consequently the exposure was often too short (injections cannot be routinely initiated before 5 weeks). Except psychological support, there is no treatment whose benefit has been proved in unexplained RM, in the presence or in the absence of an inherited thrombophilia. Moreover the absence of benefit of some treatments has been clearly demonstrated. Although the prognostic is not so poor (live-birth rates around 70%), proposed therapeutic interventions are sometimes excessive (regarding possible side effects and cost): as intravenous immunoglobulins, assisted procreation ...anti-TNF. Consequently, for the management of these distressed patients, investigating other therapeutic options is highly needed. Regarding recurrent miscarriage in women with high titers of antiphospholipid but without any other previous clinical event listed in the antiphospholipid syndrome, the benefit of antithrombotic treatment remains controversial (negative results of the HepASA trial) and hydroxychloroquine has never been assessed, although retrospective studies are encouraging. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03165136
Study type Interventional
Source University Hospital, Brest
Contact
Status Active, not recruiting
Phase Phase 3
Start date December 4, 2017
Completion date February 1, 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01419392 - Role of Sildenafil Citrate in Patients With Unexplained Recurrent Miscarriages Phase 4
Completed NCT00193674 - Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage Phase 3
Completed NCT06001060 - Distinct Alterations in Gut Microbiota Composition Among Women of Reproductive Age With Elevated Homocysteine Levels.
Recruiting NCT05034250 - Iron Status in Female Infertility and Recurrent Miscarriage
Completed NCT02681627 - Sim (Scratch in Miscarriage) Study N/A
Recruiting NCT02303171 - Use of Warfarin After the First Trimester in Pregnant Women With APS Phase 4
Completed NCT02305420 - EmbryoGen/ Blastgen for Couples With Implantation Problems or Previous Miscarriage Phase 4
Recruiting NCT05824897 - The Cohort Study of the Correlation Between Serum 25(OH)D Level and Pregnancy Outcome
Completed NCT03023137 - Walking and Dietary Modification for Recurrent Early Miscarriages N/A
Not yet recruiting NCT03132779 - Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortion Phase 1
Completed NCT02184741 - A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage Phase 3
Active, not recruiting NCT02156063 - A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL) Phase 2
Recruiting NCT03902912 - Effect of Prednisolone Treatment on Uterine Natural Killer Cells Phase 3
Not yet recruiting NCT03209063 - The Role of Prothrombin Gene and Methylenetetrahydrofolate Reductase(MTHFR) Gene Polymorphisms as Risk Factors for Recurrent Miscarriage
Completed NCT03970954 - Low-dose Interleukin-2 in Women With Unexplained Miscarriages Phase 1/Phase 2
Not yet recruiting NCT06249230 - The Analysis of Risk Factors for Recurrent Pregnancy Loss and Prediction of Pregnancy Loss Risk
Recruiting NCT05725512 - Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages Phase 4
Recruiting NCT05267678 - Nutritional Deficiency and Recurrent Miscarriage
Completed NCT02504281 - Study on the Association Between SXCI and RM and the Possible Genetic Mechanism
Completed NCT02694367 - Expression of EPK in Recurrent Miscarriage N/A